体重指数对绝经后雌激素受体阳性乳腺癌患者延长芳香化酶抑制剂治疗预后关系:SOLE试验回顾性分析
基于SOLE试验中3606例ER+/HER2-淋巴结阳性乳腺癌患者,评估BMI与延长内分泌治疗预后的关系。BMI的预后价值取决于既往内分泌治疗类型和延长治疗臂,在DRFI、BCFI和DFS中交互作用P<0.001,OS无交互作用。
要点
- BMI与年龄、肿瘤大小、阳性淋巴结数、绝经状态及既往内分泌治疗类型相关。
- BMI预后价值取决于既往内分泌治疗和延长治疗臂,DRFI、BCFI、DFS交互作用P<0.001。
- 既往用SERM和AI者,肥胖 vs 正常体重在持续来曲唑组DRFI RR=0.61,间歇组RR=2.31。
核心结论
- BMI的预后关系随辅助内分泌治疗类型和延长AI给药方式而变化,需进一步研究。
研究设计与样本
- SOLE试验(NCT00553410)回顾性分析,纳入3606例完成4-6年辅助内分泌治疗后接受5年持续或间歇来曲唑的绝经后ER+/HER2-淋巴结阳性乳腺癌患者。
主要发现
- 38.6%患者为体重过轻或正常体重,36.5%为超重,24.9%为肥胖。
- BMI与年龄、肿瘤大小、阳性淋巴结数、绝经状态及既往内分泌治疗类型相关。
- 调整分析中,BMI预后价值取决于既往内分泌治疗和延长治疗臂,DRFI、BCFI、DFS交互作用P<0.001,OS无交互作用。
- 既往5年内分泌治疗同时使用SERM和AI者,肥胖 vs 正常体重在持续来曲唑组DRFI的RR=0.61(95%CI: 0.42-0.90),在间歇来曲唑组DRFI的RR=2.31(95%CI: 1.41-3.78)。
关键数值与推荐
- BMI分组:体重过轻或正常体重38.6%,超重36.5%,肥胖24.9%。
- DRFI、BCFI、DFS交互作用P<0.001,OS无交互作用。
- 持续来曲唑组肥胖 vs 正常体重DRFI RR=0.61(95%CI: 0.42-0.90);间歇来曲唑组RR=2.31(95%CI: 1.41-3.78)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Obesity is associated with a greater risk of developing distant recurrences in patients with estrogen receptor-positive (ER+) breast cancer. This association is however poorly investigated in patients treated with extended endocrine treatment (ET). We therefore evaluated the prognostic role of BMI in the SOLE trial, where postmenopausal patients, after having completed 4-6 years of adjuvant ET, were treated with 5 additional years of continuous or intermittent letrozole. PATIENTS & METHODS: We considered the 3606 patients with ER+ /HER2- lymph node-positive BC with available BMI from the SOLE trial (NCT00553410). Distant-recurrence free interval (DRFI) was the main endpoint, and breast cancer-free interval (BCFI), disease-free survival (DFS) and overall survival (OS) secondary endpoints. Adjusted risk ratios (RR) for distant metastases were estimated with crude cumulative incidence models. RESULTS: 38.6 % of the patients were underweight or normal weight, 36.5 % overweight and 24.9 % obese. BMI was associated with age, tumor size, number of positive lymph nodes, menopausal status and type of prior ET. In the adjusted analyses, the prognostic value of BMI was dependent on prior ET and extended ET arm (second-order interaction p-value<0.001 for DRFI, BCFI and DFS, but not for OS). For instance, in patients treated with both a selective estrogen receptor modulator and an aromatase inhibitor in the first five years, obesity, as compared to normal-weight, was associated with better (RRDRFI=0.61, 95 %CI: 0.42-0.90) and worse (RRDRFI=2.31, 95 %CI: 1.41-3.78) outcomes in the adjusted models, in patients treated with continuous and intermittent letrozole in the extended ET, respectively. CONCLUSION: We observed that the prognostic relation of BMI changes according to the type of adjuvant ET and mode of administration of extended AI. This warrants further investigation.
引用
- Biganzoli G, Isnaldi E, Richard F, et al. Prognostic relation of body mass index on extended aromatase inhibition treatment in postmenopausal patients with estrogen receptor positive breast cancer: A retrospective analysis of the SOLE trial. Eur J Cancer. 2025. PMID: 40286474. doi:10.1016/j.ejca.2025.115438
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。